Literature DB >> 29126304

SDHC Promoter Methylation, a Novel Pathogenic Mechanism in Parasympathetic Paragangliomas.

Cristóbal Bernardo-Castiñeira1, Nuria Valdés2, Marta I Sierra3, Inés Sáenz-de-Santa-María1, Gustavo F Bayón3, Raúl F Perez3,4, Agustín F Fernández3, Mario F Fraga4, Aurora Astudillo5, Rafael Menéndez6, Belén Fernández7, Maribel Del Olmo8, Carlos Suarez1, María-Dolores Chiara1.   

Abstract

Context: Germline mutations in the succinate dehydrogenase A, B, C, and D genes (collectively, SDHx) predispose to the development of paragangliomas (PGLs) arising at the parasympathetic or sympathetic neuroendocrine systems. SDHx mutations cause absence of tumoral immunostaining for SDHB. However, negative SDHB immunostaining has also been found in a subset of PGLs that lack SDHx mutations. Settings: Here, we report the comprehensive molecular characterization of one such a tumor of parasympathetic origin compared with healthy paraganglia and other PGLs with or without SDHx mutations.
Results: Integration of multiplatform data revealed somatic SDHC methylation and loss of the 1q23.3 region containing the SDHC gene. This correlated with decreased SDHC messenger RNA (mRNA) and protein levels. Furthermore, another genetic event found affected the VHL gene, which showed a decreased DNA copy number, associated with low VHL mRNA levels, and an absence of VHL protein detected by immunohistochemistry. In addition, the tumor displayed a pseudohypoxic phenotype consisting in overexpression of the hypoxia-inducible factor (HIF)-1α and miR-210, as well as downregulation of the iron-sulfur cluster assembly enzyme (ISCU) involved in SDHB maturation. This profile resembles that of SDHx- or VHL-mutated PGLs but not of PGLs with decreased VHL copy number, pointing to SDHC rather than VHL as the pathogenic driver. Conclusions: Collectively, these findings demonstrate the potential importance of both the SDHC epigenomic event and the activation of the HIF-1α/miR-210/ISCU axis in the pathogenesis of SDHx wild-type/SDHB-negative PGLs. To our knowledge, this is the first case of a sporadic parasympathetic PGL that carries silencing of SDHC, fulfilling the two-hit Knudson's model for tumorigenesis.
Copyright © 2017 Endocrine Society

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29126304     DOI: 10.1210/jc.2017-01702

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  3 in total

1.  Clinical and histopathological principles for the diagnosis of a recurrent paraganglioma of the jugular foramen initially diagnosed as a middle ear adenoma: illustrative case.

Authors:  Jeffrey M Breton; Knarik Arkun; Arthur S Tischler; Adnan S Qamar; Jonathan S Sillman; Carl B Heilman
Journal:  J Neurosurg Case Lessons       Date:  2021-08-02

2.  SDHC epi-mutation testing in gastrointestinal stromal tumours and related tumours in clinical practice.

Authors:  Ruth T Casey; Rogier Ten Hoopen; Eguzkine Ochoa; Benjamin G Challis; James Whitworth; Philip S Smith; Jose Ezequiel Martin; Graeme R Clark; Fay Rodger; Mel Maranian; Kieren Allinson; Basetti Madhu; Thomas Roberts; Luis Campos; Joanne Anstee; Soo-Mi Park; Alison Marker; Colin Watts; Venkata R Bulusu; Olivier T Giger; Eamonn R Maher
Journal:  Sci Rep       Date:  2019-07-15       Impact factor: 4.379

3.  Head/neck paragangliomas: focus on tumor location, mutational status and plasma methoxytyramine.

Authors:  Susan Richter; Bei Qiu; Mirthe Ghering; Carola Kunath; Georgiana Constantinescu; Charlotte Luths; Christina Pamporaki; Nicole Bechmann; Leah Meuter; Aleksandra Kwapiszewska; Timo Deutschbein; Svenja Nölting; Mirko Peitzsch; Mercedes Robledo; Aleksander Prejbisz; Karel Pacak; Volker Gudziol; Henri J L M Timmers; Graeme Eisenhofer
Journal:  Endocr Relat Cancer       Date:  2022-03-21       Impact factor: 5.678

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.